Suchen
GeneDx Holdings Corp
WGSZur Watchlist hinzufügen
39.920USD
+0.980+2.52%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.18BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über GeneDx Holdings Corp Unternehmen
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
GeneDx Holdings Corp Informationen
BörsenkürzelWGS
Name des UnternehmensGeneDx Holdings Corp
IPO-datumSep 04, 2020
CEOStueland (Katherine A)
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 04
Addresse333 Ludlow Street
StadtSTAMFORD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl06902
Telefon18887291206
Websitehttps://sema4.com/
BörsenkürzelWGS
IPO-datumSep 04, 2020
CEOStueland (Katherine A)
Führungskräfte von GeneDx Holdings Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
4.44M
+99.55%
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
185.99K
-20.43%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
34.94K
+0.28%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
26.33K
-25.95%
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
4.44M
+99.55%
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
185.99K
-20.43%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
34.94K
+0.28%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
26.33K
-25.95%
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Patients with third party insurance
345.24M
80.75%
Institutional customers
70.07M
16.39%
Other
10.87M
2.54%
Self pay patients
1.36M
0.32%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Patients with third party insurance
345.24M
80.75%
Institutional customers
70.07M
16.39%
Other
10.87M
2.54%
Self pay patients
1.36M
0.32%
Aktionärsstatistik
Aktualisiert: 14 hours ago
Aktualisiert: 14 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Meister (Keith A)
14.95%
Corvex Management LP
14.93%
Icahn School of Medicine at Mount Sinai
4.63%
OPKO Health Inc
4.62%
Westfield Capital Management Company, L.P.
4.61%
Andere
56.27%
Aktionäre
Aktionäre
Anteil
Meister (Keith A)
14.95%
Corvex Management LP
14.93%
Icahn School of Medicine at Mount Sinai
4.63%
OPKO Health Inc
4.62%
Westfield Capital Management Company, L.P.
4.61%
Andere
56.27%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
35.13%
Investment Advisor
33.09%
Hedge Fund
32.91%
Corporation
10.37%
Research Firm
6.51%
Individual Investor
1.81%
Pension Fund
0.40%
Bank and Trust
0.39%
Sovereign Wealth Fund
0.23%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
456
30.28M
113.16%
--
2026Q1
549
32.98M
111.70%
+333.95K
2025Q4
500
30.62M
105.95%
-3.52M
2025Q3
446
32.52M
112.51%
-918.42K
2025Q2
397
34.23M
119.24%
+1.02M
2025Q1
398
32.79M
115.46%
-47.86K
2024Q4
341
29.17M
104.22%
+1.72M
2024Q3
289
26.18M
97.50%
+377.48K
2024Q2
262
24.98M
95.33%
+588.25K
2024Q1
260
22.13M
86.19%
+1.41M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Corvex Management LP
3.06M
10.44%
--
--
Dec 31, 2025
Icahn School of Medicine at Mount Sinai
1.37M
4.69%
-1.35M
-49.50%
Feb 21, 2025
OPKO Health Inc
1.37M
4.68%
-800.83K
-36.88%
Nov 20, 2024
Westfield Capital Management Company, L.P.
1.02M
3.48%
+474.17K
+87.15%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
1.34M
4.58%
+25.70K
+1.95%
Dec 31, 2025
ARK Investment Management LLC
604.56K
2.06%
+157.58K
+35.25%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.02M
3.48%
+17.80K
+1.78%
Dec 31, 2025
Summit Partners Public Asset Management, LLC
920.59K
3.14%
+97.02K
+11.78%
Dec 31, 2025
Oracle Investment Management, Inc.
884.65K
3.02%
-5.30K
-0.60%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Global X Genomics & Biotechnology ETF
3.84%
Franklin Genomic Advancements ETF
3.47%
Clough Hedged Equity ETF
2.89%
Clough Select Equity ETF
2.65%
State Street SPDR S&P Health Care Services ETF
2.27%
Harbor Health Care ETF
1.85%
Innovator IBD Breakout Opportunities ETF
1.52%
ARK Genomic Revolution ETF
1.29%
Main Thematic Innovation ETF
1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
1.18%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil3.84%
Franklin Genomic Advancements ETF
Anteil3.47%
Clough Hedged Equity ETF
Anteil2.89%
Clough Select Equity ETF
Anteil2.65%
State Street SPDR S&P Health Care Services ETF
Anteil2.27%
Harbor Health Care ETF
Anteil1.85%
Innovator IBD Breakout Opportunities ETF
Anteil1.52%
ARK Genomic Revolution ETF
Anteil1.29%
Main Thematic Innovation ETF
Anteil1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.18%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
